Abstract
Normal stem cells and cancer stem cells (CSCs) share similar properties, in that both have the capacity to self-renew and differentiate into multiple cell types. In both the normal stem cell and cancer stem cell fields, there has been a great need for a universal marker that can effectively identify and isolate these rare populations of cells in order to characterize them and use this information for research and therapeutic purposes. Currently, it would appear that certain isoenzymes of the aldehyde dehydrogenase (ALDH) superfamily may be able to fulfill this role as a marker for both normal and cancer stem cells. ALDH has been identified as an important enzyme in the protection of normal hematopoietic stem cells, and is now also widely used as a marker to identify and isolate various types of normal stem cells and CSCs. In addition, emerging evidence suggests that ALDH1 is not only a marker for stem cells, but may also play important functional roles related to self-protection, differentiation, and expansion. This comprehensive review discusses the role that ALDH plays in normal stem cells and CSCs, with focus on ALDH1 and ALDH3A1. Discrepancies in the functional themes between cell types and future perspectives for therapeutic applications will also be discussed.
Similar content being viewed by others
References
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105–111.
Lapidot T., Sirard C., Vormoor J., et al. (1994).A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645–648.
Douville, J., Beaulieu, R., & Balicki, D. (2009). ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells and Development, 18, 17–25.
Moreb, J. S. (2008). Aldehyde dehydrogenase as a marker for stem cells. Current Stem Cell Research & Therapy, 3, 237–246.
Marchitti, S. A., Brocker, C., Stagos, D., & Vasiliou, V. (2008). Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opinion on Drug Metabolism & Toxicology, 4, 697–720.
Vasiliou, V., & Nebert, D. W. (2005). Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Human Genomics, 2, 138–143.
Black, W. J., Stagos, D., Marchitti, S. A., et al. (2009). Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature. Pharmacogenetics and Genomics, 19, 893–902.
Sladek, N. E. (2003). Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. Journal of Biochemical and Molecular Toxicology, 17, 7–23.
Stewart, M. J., Malek, K., & Crabb, D. W. (1996). Distribution of messenger RNAs for aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues. Journal of Investigative Medicine, 44, 42–46.
Yanagawa, Y., Chen, J. C., Hsu, L. C., & Yoshida, A. (1995). The transcriptional regulation of human aldehyde dehydrogenase I gene. The structural and functional analysis of the promoter. The Journal of Biological Chemistry, 270, 17521–17527.
Vasiliou, V., & Pappa, A. (2000). Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. Pharmacology, 61, 192–198.
Elizondo, G., Corchero, J., Sterneck, E., & Gonzalez, F. J. (2000). Feedback inhibition of the retinaldehyde dehydrogenase gene ALDH1 by retinoic acid through retinoic acid receptor alpha and CCAAT/enhancer-binding protein beta. The Journal of Biological Chemistry, 275, 39747–39353.
Giogianni, F., Bridson, P. K., Sorrentino, B. P., Pohl, J., & Blakley, R. L. (2000). Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3. Biochemical Pharmacology, 60, 325–338.
Magni, M., Shammah, S., Schiro, R., Mellado, W., Dalla-Favera, R., & Gianni, A. M. (1996). Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood, 87, 1097–1103.
Moreb, J. S., Schweder, M., Gray, B. A., Zucali, J. R., & Zori, R. (1998). In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Human Gene Therapy, 9, 611–619.
Kastan, M. B., Schlaffer, E., Russo, J. E., Colvin, O. M., Civin, C. I., & Hilton, J. (1990). Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood, 75, 1947–1940.
Dipple, K. M., & Crabb, D. W. (1993). The mitochondrial aldehyde dehydrogenase gene resides in an HTF island but is expressed in a tissue-specific manner. Biochemical and Biophysical Research Communications, 193, 420–427.
Mirabelli, P., Di Noto, R., Lo, Pardo, C., et al. (2008).Extended flow cytometry characterization of normal bone marrow progenitor cells by simultaneous detection of aldehyde dehydrogenase and early hematopoietic antigens: implication for erythroid differentiation studies. BMC Physiol, 8.
Croker, A. K., Goodale, D., Chu, J., et al. (2008). High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. Journal of Cellular and Molecular Medicine, 13, 2236–2252.
Burger, P. E., Gupta, R., Xiong, X., et al. (2009). High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells, 27, 2220–2228.
Chute, J. P., Muramoto, G. G., Whitesides, J., et al. (2006). Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 103, 11707–11712.
Corti, S., Locatelli, F., Papadimitriou, D., et al. (2006). Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells, 24, 975–985.
Fallon, P., Gentry, T., Balber, A. E., et al. (2003). Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. British Journal Haematology, 122, 99–108.
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555–567.
Jones, R. J., Barber, J. P., Vala, M. S., et al. (1995). Assessment of aldehyde dehydrogenase in viable cells. Blood, 85, 2742–2746.
Russo, J. E. (1997). Inhibition of mouse and human class 1 aldehyde dehydrogenase by 4-(N, N-dialkylamino)benzaldehyde compunds. Advances in Experimental Medicine and Biology, 414, 217–224.
Storms, R. W., Trujillo, A. P., Springer, J. B., et al. (1999). Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proceedings of the National Academy of Sciences of the United States of America, 96, 9118–9123.
Huang, E. H., Hynes, M. J., Zhang, T., et al. (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Research, 69, 3382–3389.
Pearce, D. J., & Bonnet, D. (2007). The combined use of Hoechst efflux ability and aldehyde dehydrogenase activity to identify murine and human hematopoietic stem cells. Experimental Hematology, 35, 1437–1446.
Levi, B. P., Yilmaz, O. H., Duester, G., & Morrison, S. J. (2009). Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous system. Blood, 113, 1670–1680.
Muramoto, G. G., Russell, J. L., Safi, R., et al. (2010). Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity. Stem Cells, 28, 523–534.
Armstrong, L., Stojkovic, M., Dimmick, I., et al. (2004). Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells, 22, 1142–1151.
Vaidyanathan, G., Song, H., Affleck, D., et al. (2009). Targeting aldehyde dehydrogenase: a potential approach for cell labeling. Nuclear Medicine and Biology, 36, 919–929.
Hess, D. A., Wirthlin, L., Craft, T. P., et al. (2006). Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood, 107, 2162–2169.
Cai, J., Cheng, A., Luo, Y., et al. (2004). Membrane properties of rat embryonic multipotent neural stem cells. Journal of Neurochemistry, 88, 212–226.
Capoccia, B. J., Robson, D. L., Levac, K. D., et al. (2009). Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blod, 113, 5340–5351.
Hess, D. A., Craft, T. P., Wirthlin, L., et al. (2008). Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells, 26, 611–620.
Hess, D. A., Meyerrose, T. E., Wirthlin, L., et al. (2004). Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood, 104, 1648–1655.
Rice, K. L., Izon, D. J., Ford, J., Boodhoo, A., Kees, U. R., & Greene, W. K. (2008). Overexpression of stem cell associated ALDH1A1, a target of the leukemogenic transcription factor TLX1/HOX11, inhibits lymphopoiesis and promotes myelopoiesis in murine hematopoietic progenitors. Leukemia Research, 32, 873–883.
Sondergaard, C. S., Hess, D. A., Maxwell, D. J., et al. (2010).Human cord blood progenitors with high aldehyde dehydrogenase activity improve vascular density in a model of acute myocardial infarction. J Transl Med, 8.
Storms, R. W., Green, P. D., Safford, K. M., et al. (2005). Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood, 106, 95–102.
Zhou, P., Hohm, S., Olusanya, Y., Hess, D. A., & Nolta, J. A. (2009). Human progenitor cells with high aldehyde dehydrogenase activity efficiently engraft into damaged liver in a novel model. Hepatology, 49, 1992–2000.
Estes, B. T., Wu, A. W., Storms, R. W., & Guilak, F. (2006). Extended passaging, but not aldehyde dehydrogenase activity, increases the chondrogenic potential of human adipose-derived adult stem cells. Journal of Cellular Physiology, 209, 987–995.
Jean, E., Laoudj-Chenivesse, D., Notarnicola, C., et al. (2009).Aldehyde dehydrogenase activity promotes survival of human muscle precursor cells. J Cell Mol Med, Epub ahead of print. Oct. 16.
Sladek, N. E. (1999). Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Current Pharmaceutical Design, 5, 607–625.
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.
Tlsty, T., & Coussens, L. M. (2006). Tumor stroma and regulation of cancer development. Annual Review of Pathology, 1, 119–150.
Cohnheim, J. (1867). Ueber entzundung und eiterung. Path Anat Physiol Klin Med, 40, 1–79.
Durante, F. (1874). Nesso fisio-pathologico tra la struttura dei nei matemi e la genesi di alcuni tumori maligni. Arch Memor Observ Chir Pract, 11, 217–226.
Wicha, M. S., Liu, S., & Dontu, G. (2006). Cancer stem cells: an old idea—a paradigm shift. Cancer Research, 66, 1883–1880.
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983–3988.
Fillmore, C. M., & Kuperwasser, C. (2008). Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Research, 10, R25.
Ponti, D., Costa, A., Zaffaroni, N., et al. (2005). Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Research, 65, 5506–5511.
Sheridan, C., Kishimoto, H., Fuchs, R. K., et al. (2006). CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Research, 8, R59.
Madid, Z., Mehrjerdi, A. Z., Sharifi, A. M., Molanaei, S., Shahzadi, S. Z., & Asadi-Lari, M. (2009). CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immunity, 9, 4.
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research, 65, 10946–10951.
Hermann, P. C., Huber, S. L., Herrler, T., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1, 313–323.
Li, C., Heidt, D. G., Dalerba, P., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67, 1030–1037.
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007). A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature, 445, 106–110.
Ricci-Vitiani, L., Lombardi, D. G., Poilozzi, E., et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature, 445, 111–115.
Singh, S. K., Hawkins, C., Clarke, I. D., et al. (2004). Identification of human brain tumor initiating cells. Nature, 432, 396–401.
Yang, Z. F., Ho, D. W., Ng, M. N., et al. (2008). Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell, 13, 153–166.
Lingala, S., Cui, Y. Y., Chen, X., et al. (2010). Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Experimental and Molecular Pathology, 89, 27–35.
Lugli, A., Iezzi, G., Hostettler, I., et al. (2010).Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer, Epub ahead of print.
Brennan, S. K., Meade, B., Wang, Q., Merchant, A. A., Kowalski, J., & Matsui, W. (2010).Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood, Epub ahead of print. Jun. 22.
Bortolomai, I., Canevari, S., Facelti, I., et al. (2010).Tumor initiating cells: Development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle, 9, Epub ahead of print. Mar. 4.
Carpentino, J. E., Hynes, M. J., Appelman, H. D., et al. (2009). Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Research, 69, 8208–8212.
Clay, M. R., Tabor, M., Owen, J. H., et al. (2010).Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck, Epub ahead of print. Jan. 13.
Deng, S., Yang, X., Lassus, H., et al. (2010). Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE, 5, e10277.
Li, T., Su, Y., Mei, Y., et al. (2010). ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Laboratory Investigation, 90, 234–244.
Rasheed, Z. A., Yang, J., Wang, Q., et al. (2010). Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. Journal of the National Cancer Institute, 102, 340–351.
Su, Y., Qiu, Q., Zhang, X., et al. (2010). Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiology, Biomarkers & Prevention, 19, 327–337.
Sun, S., & Wang, Z. (2010). ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis. Biochemical and Biophysical Research Communications, 396, 843–848.
Tanei, T., Morimoto, K., Shimazu, K., et al. (2009). Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clinical Cancer Research, 15, 4234–4241.
Ucar, D., Cogle, C. R., Zucali, J. R., et al. (2009). Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chemico Biological Interactions, 178, 48–55.
van den Hoogen, C., van der Horst, G., Cheung, H., et al. (2010). High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Research, 70, 5163–5173.
Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nature Reviews Cancer, 8, 755–768.
Sreerama, L., & Sladek, N. E. (1997). Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies. Clinical Cancer Research, 3, 1901–1914.
Charafe-Jauffret, E., Ginestier, C., Iovino, F., et al. (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clinical Cancer Research, 16, 45–55.
Chang, B., Liu, G., Xue, F., et al. (2009). ALDH1 expression correlates with favorable prognosis in ovarian cancers. Modern Pathology, 22, 817–823.
Luo, P., Wang, A., Payne, K. J., et al. (2007). Intrinsic retinoic acid receptor alpha-cyclin-dependent kinase-activating kinase signaling involves coordination of the restricted proliferation and granulocytic differentiation of human hematopoietic stem cells. Stem Cells, 25, 2628–2637.
Simandi, Z., Balint, B. L., Poliska, S., Ruhl, R., & Nagy, L. (2010). Activation of retinoic acid receptor signaling coordinates lineage commitment of spontaneously differentiating mouse embryonic stem cells in embryoid bodies. FEBS Letters, 584, 3123–3130.
Su, Z. Y., Li, Y., Zhao, X. L., & Zhang, M. (2010). All-trans retinoic acid promotes smooth muscle cell differentiation of rabbit bone marrow-derived mesenchymal stem cells. Journal of Zhejiang University. Science B, 11, 489–496.
Tonge, P. D., & Andrews, P. W. (2010). Retinoic acid directs neuronal differentiation of human pluripotent stem cell lines in a non-cell-autonomous manner. Differentiation, 80, 20–30.
Tallman, M. S., Andersen, J. W., Schiffer, C. A., et al. (1997). All-trans-retinoic acid in acute promyelocytic leukemia. The New England Journal of Medicine, 337, 1021–1028.
Ginestier, C., Wicinski, J., Cervera, N., et al. (2009). Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle, 8, 3297–3302.
Moreb, J. S., Gabr, A., Vartikar, G. R., Gowda, S., Zucali, J. R., & Mohuczy, D. (2005). Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. The Journal of Pharmacology and Experimental Therapeutics, 312, 339–345.
Moreb, J. S., Mohuczy, D., Ostmark, B., & Zucali, J. R. (2007). RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemotherapy and Pharmacology, 59, 127–136.
Duester, G., Mic, F. A., & Molotkov, A. (2003). Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism to retinoic acid. Chemico Biological Interactions, 143–144, 201–210.
Zhao, D., McCaffery, P., Ivins, K. J., et al. (1996). Molecular identification of a major retinoic-acid-synthesizing enzyme, a retinaldehyde-specific dehydrogenase. European Journal of Biochemistry, 240, 15–22.
Appel, B., & Eisen, J. S. (2003). Retinoids run rampant: multiple roles during spinal cord and motor neuron development. Neuron, 40, 461–464.
Elizondo, G., Medina-Diaz, I. M., Cruz, R., Gonzalez, F. J., & Vega, L. (2009). Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction. Biochemical Pharmacology, 77, 248–257.
Deak, K. L., Dickerson, M. E., Linney, E., et al. (2005). Analysis of ALDH1A2, CYP26A1, CYP26B1, CRABP1, and CRABP2 in human neural tube defects suggests a possible association with alleles in ALDH1A2. Birth Defects Research. Part A: Clinical and Molecular Teratology, 73, 868–875.
Tanabe, H., Ohhira, M., Ohtsubo, T., Watari, J., Yokota, K., & Kohgo, Y. (1999). Genetic polymorphism of aldehyde dehydrogenase 2 in patients with upper aerodigestive tract cancer. Alcoholism, Clinical and Experimental Research, 23, 17S–20S.
Minami, J., Todoroki, M., Ishimitsu, T., et al. (2002). Effects of alcohol intake on ambulatory blood pressure, heart rate, and heart rate variability in Japanese men with different ALDH2 genotypes. Journal of Human Hypertension, 16, 345–351.
Rizzo, W. B. (2007). Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Molecular Genetics and Metabolism, 90, 1–9.
Geraghty, M. T., Vaughn, D., Nicholson, A. J., et al. (1998). Mutations in the Delta1-pyrroline 5-carboxylate dehydrogenase gene cause type II hyperprolinemia. Human Molecular Genetics, 7, 1411–1415.
Gibson, K. M., Christensen, E., Jakobs, C., et al. (1997). The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics, 99, 567–574.
Mills, P. B., Footitt, E. J., Mills, K. A., et al. (2010). Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain, 133, 2148–2159.
Hilton, J. (1984). Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Research, 44, 5156–5160.
Kohn, F. R., & Sladek, N. E. (1987). Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557). Biochemical Pharmacology, 36, 2805–2811.
Kohn, F. R., Landkamer, G. J., Manthey, C. L., Ramsay, N. K., & Sladek, N. E. (1987). Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines. Cancer Research, 47, 3180–3185.
Sahovic, E. A., Colvin, M., Hilton, J., & Ogawa, M. (1988). Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Cancer Research, 48, 1223–1226.
Moreb, J., Zucali, J. R., Zhang, Y., Colvin, M. O., & Gross, M. A. (1992). Role of aldehyde dehydrogenase in the protection of hematopoietic progenitor cells from 4-hydroperoxycyclophosphamide by interleukin 1 beta and tumor necrosis factor. Cancer Research, 52, 1770–1774.
Moreb, J., Turner, C. H., Sreerama, L., Zucali, J. R., Sladek, N. E., & Schweder, M. (1995). Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells. Leukaemia & Lymphoma, 20, 77–84.
Bunting, K. D., & Townsend, A. J. (1996). De novo expression of transfected human class I aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. The Journal of Biological Chemistry, 271, 11884–11890.
Takebe, N., Zhao, S. C., Adhikari, D., et al. (2001). Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Molecular Therapy, 3, 88–96.
Sladek, N. E., Kollander, R., Sreerama, L., & Kiang, D. T. (2002). Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemotherapy and Pharmacology, 49, 309–321.
Sreerama, L., & Sladek, N. E. (1995). Human breast adenocarcinoma MCF-7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide. Drug Metabolism and Disposition, 23, 1080–1084.
Sreerama, L., & Sladek, N. E. (2001). Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens. Cancer Chemotherapy and Pharmacology, 47, 255–262.
Morimoto, K., Kim, S. J., Tanei, T., et al. (2009).Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci, 100, Epub. 2009 Mar. 2009.
Kitahara, O., Katagiri, T., Tsunoda, T., Harima, Y., & Nakmura, Y. (2002). Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia, 4, 295–303.
Prasmickaite, L., Engesaeter, B. Ø., Skrbo, N., et al. (2010). Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS ONE, 5, e10731.
Greene, W. K., Bahn, S., Masson, N., & Rabbitts, T. H. (1998). The T-cell oncogenic protein HOX11 activates Aldh1 expression in NIH 3T3 cells but represses its expression in mouse spleen development. Molecular and Cellular Biology, 18, 7030–7037.
Croker, A. K., & Allan, A. L. (2009).All-trans retinoic acid (ATRA) reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ breast cancer cells. AACR Adv in Breast Can Meeting, Abstract, October, 2009.
Budd, G. T., Adamson, P. C., Gupta, M., et al. (1998). Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clinical Cancer Research, 4, 635–642.
Koelling, T. M., Yeager, A. M., Hilton, J., Haynie, D. T., & Wiley, J. M. (1990). Development and characterization of a cyclophosphamide-resistant subline of acute myeloid leukemia in the Lewis x Brown Norway hybrid rat. Blood, 76, 1209–1213.
Marcato, P., Dean, C. A., Giacomantonio, C. A., & Lee, P. W. K. (2009). If cancer stem cells are resistant to current therapies, what’s next? Future Oncology, 5, 747–750.
Hanna, M. C., & Blackstone, C. (2009). Interaction of the SPG21 protein ACP33/maspardin with the aldehyde dehydrogenase ALDH16A1. Neurogenetics, 10, 217–228.
Hall, P. E., Lathia, J. D., Miller, N. G., Caldwell, M. A., & Ffrench-Constant, C. (2006). Integrins are markers of human neural stem cells. Stem Cells, 24, 2078–2084.
Wang, S. S., Asfaha, S., Okumura, T., et al. (2009). Fibroblastic colony-forming unit bone marrow cells delay progression to gastric dysplasia in a helicobacter model of gastric tumorigenesis. Stem Cells, 27, 2301–2311.
Patki, S., Kadam, S., Chandra, V., & Bhonde, R. (2010). Human breast milk is a rich source of multipotent mesenchymal stem cells. Human Cell, 23, 35–40.
Yablonka-Reuveni, Z., Day, K., Vine, A., & Shefer, G. (2008). Defining the transcriptional signature of skeletal muscle stem cells. Journal of Animal Science, 86, E207–E216.
Beier, D., Hau, P., Proescholdt, M., et al. (2007). CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Research, 67, 4010–4015.
Vander Griend, D. J., Karthaus, W. L., Dalrmple, S., Meeker, A., DeMarzo, A. M., & Isaacs, J. T. (2008). The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Research, 68, 9703–9711.
Miki, J., Furusato, B., Li, H., et al. (2007). Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Research, 67, 3153–3161.
Gao, M. Q., Choi, Y. P., Kang, S., Youn, J. H., & Cho, N. H. (2010). CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene, 29, 2672–2680.
Curley, M. D., Therrien, V. A., Cummings, C. L., et al. (2009). CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells, 27, 2875–2883.
Kong, Y., Yoshida, S., Saito, Y., et al. (2008). CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia, 22, 1207–1213.
Ailles, L., & Prince, M. (2009). Cancer stem cells in head and neck squamous cell carcinoma. Methods in Molecular Biology, 568, 175–193.
Bertolini, G., Roz, L., Perego, P., et al. (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proceedings of the National Academy of Sciences of the United States of America, 106, 16281–16286.
Tirino, V., Camerlingo, R., Franco, R., et al. (2009). The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. European Journal of Cardiothoracic Surgery, 36, 446–453.
Acknowledgements
We thank members of our laboratory and our collaborators for their research work and helpful discussions. The authors’ research on ALDH and CSCs is supported by research grants from the Ontario Institute for Cancer Research (#08NOV230), and the Canada Foundation for Innovation (#13199) (to ALA). IM is the recipient of a Canadian Institute of Health Research (CIHR) Strategic Training Program Scholarship and a Translational Breast Cancer Scholarship through the London Regional Cancer Program. ALA is supported by a CIHR New Investigator Award and an Early Researcher Award from the Ontario Ministry of Research and Innovation.
Conflict of interest
The authors declare no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ma, I., Allan, A.L. The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells. Stem Cell Rev and Rep 7, 292–306 (2011). https://doi.org/10.1007/s12015-010-9208-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12015-010-9208-4